Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy

Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extra...

Full description

Saved in:
Bibliographic Details
Published in:Journal of asthma and allergy 2012-01, Vol.5 (default), p.51-59
Main Author: Macdonald, Susan M
Format: Article
Language:English
Subjects:
AKT protein
Allergic reaction
Allergies
Allergy
Asthma
Care and treatment
Cytokines
Health aspects
Histamine
Homology
Immunoglobulin E
Immunoglobulin G
Inflammatory diseases
Inositol
Kinases
Leukocytes (basophilic)
Leukocytes (eosinophilic)
Lymphocytes B
Lymphocytes T
myo-Inositol-1 (or 4)-monophosphatase
Physiological aspects
Review
Signal transduction
Therapeutic applications
Tumor proteins
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extracellular functioning, and its potential role as a therapeutic target in asthma and allergy. The cells and cytokines produced when stimulated or primed by HRF/TCTP are detailed as well as the downstream signaling pathway that HRF/TCTP elicits. While it was originally thought that HRF/TCTP interacted with IgE, the finding that cells not binding IgE also respond to HRF/TCTP called this interaction into question. HRF/TCTP, or at least its mouse counterpart, appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells, and B cells. Since many of the cells activated by HRF/TCTP participate in the allergic response, extracellular functions of HRF/TCTP may exacerbate the allergic, inflammatory cascade. Particularly exciting is that small molecule agonists of Src homology 2-containing inositol phosphatase-1 have been shown to modulate the phosphoinositide 3-kinase/AKT pathway and may control inflammatory disorders. This review discusses this possibility in light of HRF/TCTP.
ISSN:1178-6965
1178-6965
DOI:10.2147/jaa.s28868